NAV
$27.90
AUM
$789.3M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.00
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +9.46% | +7.05% | +8.49% | +11.48% | - | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | LLY | Eli Lilly and Co | 15.01% |
| 2 | JNJ | Johnson & Johnson | 8.73% |
| 3 | ABBV | AbbVie Inc | 6.19% |
| 4 | MRK | Merck & Co Inc | 4.72% |
| 5 | ROP.SW | Roche Holding AG Ordinary Shares new | 4.70% |
| 6 | NOVN.SW | Novartis AG Registered Shares | 4.57% |
| 7 | AZN.L | AstraZeneca PLC | 4.37% |
| 8 | GILD | Gilead Sciences Inc | 4.27% |
| 9 | AMGN | Amgen Inc | 4.16% |
| 10 | PFE | Pfizer Inc | 3.82% |
The fund uses a “passive management” approach to track the performance, before fees and expenses, of the index. The index is constructed using a rules-based methodology that identifies companies in the pharmaceutical and/or biotechnology industries with publicly traded ordinary shares listed on major stock exchanges in developed markets, as classified by BITA GmbH. Under normal circumstances, the fund will invest at least 80% of the fund’s net assets in component securities that make up the index. The fund is non-diversified.
Inception Date: 2025-11-25